Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST – Rapid vs conventional titration of quetiapine IR in acute psychosis
2006-006426-26Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quetiapine in schizophrenia, schizoaffective disorder, Schizophrenia Spectrum Disorders (SSD) and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoint: Change in PANSS-EC from baseline to Day 5. Started Dec 2006; status: terminated.
02
Drugs
quetiapine
03
Conditions
schizophreniaschizoaffective disorderSchizophrenia Spectrum Disorders (SSD)bipolar disorder (BD)
Beyond the preview
Go deeper on 2006-006426-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006426-26.